The Food and Drug Administration’s vaccine advisory committee voted overwhelmingly against recommending the approval of a booster shot of Pfizer-BioNTech’s coronavirus vaccine for people 16 and older on Friday, but endorsed an additional dose for those most vulnerable to the virus—dealing a blow to the federal government’s plan for mass distribution of a third shot.
READ MORE: https://www.forbes.com/sites/jemimamcevoy/2021/09/17/fda-advisory-panel-recommends-against-pfizer-covid-boosters-except-for-people-over-65/?sh=3fdad99b6e1d
Stay Connected
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com
FDAbooster shotCOVID-19
0 Comments